NORCROSS, Ga., Nov. 20 Immucor, Inc.(Nasdaq: BLUD), a global leader in providing automated instrument-reagentsystems to the blood transfusion industry, announced today that Richard A.Flynt has agreed to join Immucor as Vice President and Chief Financial Officereffective December 10, 2007. The company previously announced that currentCFO Patrick Waddy intended to resign for family reasons but had agreed toremain until a replacement was hired. Mr. Waddy now becomes the company'sVice President of International Finance, reporting to Mr. Flynt, and he willassist in the transition.
Mr. Flynt is a Certified Public Accountant with more than 25 years offinancial management experience. He has most recently served as VicePresident -- Finance with McKesson Corporation in Alpharetta, Georgia. FromJuly 2004 through January 2007, he was Senior Vice President -- CorporateController & Chief Accounting Officer with Per-Se Technologies, Inc., whichwas acquired by McKesson Corporation in January 2007. From 1997 through 2004,he served in a variety of senior financial management positions with GNBTechnologies, Inc., Exide Technologies, Inc. and GTS Energy. Prior to that hehad 15 years of public accounting experience with Ernst & Young LLP.
Dr. Gioacchino De Chirico, President and Chief Executive Officer stated,"We are extremely pleased to have found an individual with the experience thatRick Flynt brings to the company. In particular, we were attracted by hisstrong background in public accounting, his expertise in dealing with complexaccounting issues, and his experience as a senior financial executive withpublicly-held companies. Coupled with Patrick Waddy's establishedinternational experience, we believe Mr. Flynt's joining the company willstrengthen our financial and accounting management as we grow ourinternational business in an increasingly complex accounting environment."
Founded in 1982, Immucor manufactures and sells a complete line ofreagents and systems used by hospitals, reference laboratories and donorcenters to detect and identify certain properties of the cell and serumcomponents of blood prior to transfusion. Immucor markets a complete familyof automated instrumentation for all of our market segments.
For more information on Immucor, please visit our website athttp://www.immucor.com.
SOURCE Immucor, Inc.